Jump to contents

Researcher Information

last modified：2025/07/14

Associate Professor　TAKEUCHI, Shinji

Mail

Faculty, Affiliation

University Hospital

College and School Educational Field


Laboratory

Academic Background

Career

(2025/04-)
(2023/09-)
(2021/11-2025/03)
(2020/01-2021/10)
(2016/10-2023/08)
(2009/05-2016/09)
(2008/04-2009/04)
(2007/04-2008/03)
(2006/05-2007/03)
(2004/04-2006/04)
(2003/04-2004/03)

Year & Month of Birth

Academic Society







International Association for the Study of Lung Cancer
European Society For Medical Oncology

Award

European Society For Medical Oncology
European Society For Medical Oncology
European Society For Medical Oncology
European Society For Medical Oncology
○International Session Award(2011/04)

Specialities

Speciality Keywords

Research Themes

Books

Papers

  • 　Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.　Shinji Takeuchi,Tetsunari Hase,Shinobu Shimizu,Masahiko Ando,Akito Hata,Haruyasu Murakami,Takahiro Kawakami,Katsuhiko Nagase,Kenichi Yoshimura,Tadami Fujiwara,Azusa Tanimoto,Akihiro Nishiyama,Sachiko Arai,Koji Fukuda,Nobuyuki Katakami,Toshiaki Takahashi,Yoshinori Hasegawa,Tun Kiat Ko,S Tiong Ong,Seiji Yano　Cancer science　111　2　561　2020/02
  • 　EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.　Takayuki Nakagawa,Shinji Takeuchi,Tadaaki Yamada,Hiromichi Ebi,Takako Sano,Shigeki Nanjo,Daisuke Ishikawa,Mitsuo Sato,Yoshinori Hasegawa,Yoshitaka Sekido,Seiji Yano　Cancer research　73　8　2428　2013/04/15
  • 　Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.　Koji Fukuda,Shinji Takeuchi,Sachiko Arai,Shigeki Nanjo,Shigeki Sato,Hiroshi Kotani,Kenji Kita,Akihiro Nishiyama,Hiroyuki Sakaguchi,Koshiro Ohtsubo,Seiji Yano　Cell reports. Medicine　5　6　101578　2024/05/15
  • 　Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET).　Shinji Takeuchi,Noriko Yanagitani,Takashi Seto,Yoshihiro Hattori,Kadoaki Ohashi,Masahiro Morise,Shingo Matsumoto,Kiyotaka Yoh,Koichi Goto,Makoto Nishio,Shizuko Takahara,Takahiro Kawakami,Yasuhito Imai,Kenichi Yoshimura,Azusa Tanimoto,Akihiro Nishiyama,Toshinori Murayama,Seiji Yano　Translational lung cancer research　10　1　314　2021/01
  • 　Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.　Koji Fukuda,Shinji Takeuchi,Sachiko Arai,Ryohei Katayama,Shigeki Nanjo,Azusa Tanimoto,Akihiro Nishiyama,Takayuki Nakagawa,Hirokazu Taniguchi,Takeshi Suzuki,Tadaaki Yamada,Hiroshi Nishihara,Hironori Ninomiya,Yuichi Ishikawa,Satoko Baba,Kengo Takeuchi,Atsushi Horiike,Noriko Yanagitani,Makoto Nishio,Seiji Yano　Cancer research　79　7　1658　2019/04/01

show all

  • 　STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.　Naohiro Yanagimura,Shinji Takeuchi,Koji Fukuda,Sachiko Arai,Azusa Tanimoto,Akihiro Nishiyama,Naohisa Ogo,Hiroyuki Takahashi,Akira Asai,Satoshi Watanabe,Toshiaki Kikuchi,Seiji Yano　NPJ precision oncology　6　1　11　2022/02/28
  • 　Intrinsic Cooperation between p16(INK4a) and p21(Waf1/Cip1) in the Onset of Cellular Senescence and Tumor Suppression In vivo　Shinji Takeuchi,Akiko Takahashi,Noriko Motoi,Shin Yoshimoto,Tomoko Tajima,Kimi Yamakoshi,Atsushi Hirao,Shigeru Yanagi,Kiyoko Fukami,Yuichi Ishikawa,Saburo Sone,Eiji Hara,Naoko Ohtani　CANCER RESEARCH　70　22　9381　2010/11
  • 　Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.　Shinji Takeuchi,Wei Wang,Qi Li,Tadaaki Yamada,Kenji Kita,Ivan S Donev,Takahiro Nakamura,Kunio Matsumoto,Eiji Shimizu,Yasuhiko Nishioka,Saburo Sone,Takayuki Nakagawa,Toshimitsu Uenaka,Seiji Yano　The American journal of pathology　181　3　1034　2012/09
  • 　Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.　Rajeswara Rao Arasada,Konstantin Shilo,Tadaaki Yamada,Jianying Zhang,Seiji Yano,Rashelle Ghanem,Walter Wang,Shinji Takeuchi,Koji Fukuda,Nobuyuki Katakami,Keisuke Tomii,Fumitaka Ogushi,Yasuhiko Nishioka,Tiffany Talabere,Shrilekha Misra,Wenrui Duan,Paolo Fadda,Mohammad A Rahman,Patrick Nana-Sinkam,Jason Evans,Joseph Amann,Elena E Tchekneva,Mikhail M Dikov,David P Carbone　Nature communications　9　1　3198　2018/08/10
  • 　Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation　Shinji Takeuchi,Koji Fukuda,Tadaaki Yamada,Sachiko Arai,Satoshi Takagi,Genichiro Ishii,Atsushi Ochiai,Shotaro Iwakiri,Kazumi Itoi,Hisanori Uehara,Hiroshi Nishihara,Naoya Fujita,Seiji Yano　CANCER SCIENCE　108　4　696　2017/04
  • 　AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.　Hirokazu Taniguchi,Tadaaki Yamada,Rong Wang,Keiko Tanimura,Yuta Adachi,Akihiro Nishiyama,Azusa Tanimoto,Shinji Takeuchi,Luiz H Araujo,Mariana Boroni,Akihiro Yoshimura,Shinsuke Shiotsu,Isao Matsumoto,Satoshi Watanabe,Toshiaki Kikuchi,Satoru Miura,Hiroshi Tanaka,Takeshi Kitazaki,Hiroyuki Yamaguchi,Hiroshi Mukae,Junji Uchino,Hisanori Uehara,Koichi Takayama,Seiji Yano　Nature communications　10　1　259　2019/01/16
  • 　Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program.　Daisuke Kotani,Atsuo Takashima,Takeshi Kato,Taroh Satoh,Toshiki Masuishi,Yoshito Komatsu,Manabu Shiozawa,Taito Esaki,Naoki Izawa,Shinji Takeuchi,Hideaki Bando,Satoru Iwasa,Hiroko Hasegawa,Toshifumi Yamaguchi,Hiroya Taniguchi,Yasunori Ushida,Toshiya Oizaki,Chiaki Inoue,Takayuki Yoshino　Clinical colorectal cancer　23　2　174　2024/03/09
  • 　FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies.　Yukata Fujiwara,Yasutoshi Kuboki,Masayuki Furukawa,Nobumasa Mizuno,Hiroki Hara,Tatsuya Ioka,Makoto Ueno,Yasuo Takahashi,Shunji Takahashi,Shinji Takeuchi,Christine Lihou,Tao Ji,Chenwei Tian,Toshio Shimizu　Cancer medicine　12　9　10597　2023/03/31
  • 　Challenges in the treatment of BRAF K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinib.　Akihiro Nishiyama,Shigeki Sato,Hiroyuki Sakaguchi,Hiroshi Kotani,Kaname Yamashita,Koushiro Ohtsubo,Shigeki Nanjo,Seiji Yano,Keishi Mizuguchi,Hiroko Ikeda,Shinji Takeuchi　Frontiers in oncology　14　1374594　2024
  • 　Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.　Shinji Takeuchi,Koji Fukuda,Tadaaki Yamada,Sachiko Arai,Satoshi Takagi,Genichiro Ishii,Atsushi Ochiai,Shotaro Iwakiri,Kazumi Itoi,Hisanori Uehara,Hiroshi Nishihara,Naoya Fujita,Seiji Yano　Cancer science　108　4　696　2017/04
  • 　Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.　Rong Wang,Tadaaki Yamada,Kenji Kita,Hirokazu Taniguchi,Sachiko Arai,Koji Fukuda,Minoru Terashima,Akihiko Ishimura,Akihiro Nishiyama,Azusa Tanimoto,Shinji Takeuchi,Koshiro Ohtsubo,Kaname Yamashita,Tomoyoshi Yamano,Akihiro Yoshimura,Koichi Takayama,Kyoichi Kaira,Yoshihiko Taniguchi,Shinji Atagi,Hisanori Uehara,Rikinari Hanayama,Isao Matsumoto,Xujun Han,Kunio Matsumoto,Wei Wang,Takeshi Suzuki,Seiji Yano　Nature communications　11　1　4607　2020/09/14
  • 　Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.　Hirokazu Taniguchi,Shinji Takeuchi,Koji Fukuda,Takayuki Nakagawa,Sachiko Arai,Shigeki Nanjo,Tadaaki Yamada,Hiroyuki Yamaguchi,Hiroshi Mukae,Seiji Yano　Cancer science　108　1　53　2017/01
  • 　Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.　Shinji Takeuchi,Kenichi Yoshimura,Tadami Fujiwara,Masahiko Ando,Shinobu Shimizu,Katsuhiko Nagase,Yoshinori Hasegawa,Toshiaki Takahashi,Nobuyuki Katakami,Akira Inoue,Seiji Yano　The journal of medical investigation : JMI　64　3.4　321　2017
  • 　Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.　Shinji Takeuchi,Koji Fukuda,Sachiko Arai,Shigeki Nanjo,Kenji Kita,Tadaaki Yamada,Eiji Hara,Hiroshi Nishihara,Hisanori Uehara,Seiji Yano　International journal of cancer　138　5　1281　2016/03/01
  • 　mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.　Daisuke Ishikawa,Shinji Takeuchi,Takayuki Nakagawa,Takako Sano,Junya Nakade,Shigeki Nanjo,Tadaaki Yamada,Hiromichi Ebi,Lu Zhao,Kazuo Yasumoto,Takahiro Nakamura,Kunio Matsumoto,Hiroshi Kagamu,Hirohisa Yoshizawa,Seiji Yano　PloS one　8　5　e62104　2013
  • 　A Supramolecular Biosensor for Rapid and High-Throughput Quantification of a Disease-Associated Niacin Metabolite.　Masaya Ueno,Hiroki Sugiyama,Feng Li,Tatsuya Nishimura,Hiroshi Arakawa,Xi Chen,Xiaoxiao Cheng,Shinji Takeuchi,Yumie Takeshita,Toshinari Takamura,Sakae Miyagi,Tadashi Toyama,Tomoyoshi Soga,Yusuke Masuo,Yukio Kato,Hiroyuki Nakamura,Hiromasa Tsujiguchi,Akinori Hara,Atsushi Tajima,Moeko Noguchi-Shinohara,Kenjiro Ono,Kenta Kurayoshi,Masahiko Kobayashi,Yuko Tadokoro,Atsuko Kasahara,Mahmoud I Shoulkamy,Katsuhiro Maeda,Tomoki Ogoshi,Atsushi Hirao　Analytical chemistry　96　36　14499　2024/08/25
  • 　Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.　Shinji Takeuchi, Tetsunari Hase, Shinobu Shimizu, Masahiko Ando, Akito Hata, Haruyasu Murakami, Takahiro Kawakami, Katsuhiko Nagase, Kenichi Yoshimura, Tadami Fujiwara, Azusa Tanimoto, Akihiro Nishiyama, Sachiko Arai, Koji Fukuda, Nobuyuki Katakami, Toshiaki Takahashi, Yoshinori Hasegawa, Tun Kiat Ko, S Tiong Ong, Seiji Yano　Cancer science　2020/02
  • 　Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis: Two Case Reports.　Hiroyuki Sakaguchi,Shigeki Nanjo,Shigeki Sato,Hiroshi Kotani,Akihiro Nishiyama,Kaname Yamashita,Koushiro Ohtsubo,Chiaki Suzuki,Masaya Shimojima,Seiji Yano,Shinji Takeuchi　Internal medicine (Tokyo, Japan)　2024/09/04
  • 　Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.　Chiaki Suzuki,Akihiro Nishiyama,Sachiko Arai,Shoichiro Tange,Atsushi Tajima,Azusa Tanimoto,Koji Fukuda,Yohei Takumi,Hiroshi Kotani,Shinji Takeuchi,Naohiro Yanagimura,Koushiro Ohtsubo,Norio Yamamoto,Koichi Omori,Seiji Yano　Cancer science　113　7　2323　2022/04/01
  • 　Pembrolizumab efficacy in a tumor mutation burden-high glioblastoma patient: A case study and implications for precision oncology.　Akihiro Nishiyama,Shigeki Sato,Hiroyuki Sakaguchi,Hiroshi Kotani,Kaname Yamashita,Koushiro Ohtsubo,Tomoko Sekiya,Atsushi Watanabe,Atsushi Tajima,Chie Shimaguchi,Keishi Mizuguchi,Hiroko Ikeda,Masashi Kinoshita,Mitsutoshi Nakada,Shinji Takeuchi　Cancer science　116　1　271　2024/10/25
  • 　The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.　Takako Sano,Shinji Takeuchi,Takayuki Nakagawa,Daisuke Ishikawa,Shigeki Nanjo,Tadaaki Yamada,Takahiro Nakamura,Kunio Matsumoto,Seiji Yano　International journal of cancer　133　2　505　2013/07/15
  • 　Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.　Shinji Takeuchi,Seiji Yano　Respiratory investigation　52　6　348　2014/11
  • 　Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.　Shinji Takeuchi,Toshinori Murayama,Kenichi Yoshimura,Takahiro Kawakami,Shizuko Takahara,Yasuhito Imai,Yoshikazu Kuribayashi,Katsuhiko Nagase,Koichi Goto,Makoto Nishio,Yoshinori Hasegawa,Miyako Satouchi,Katsuyuki Kiura,Takashi Seto,Seiji Yano　The journal of medical investigation : JMI　64　3.4　317　2017
  • 　Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.　Junya Nakade,Shinji Takeuchi,Takayuki Nakagawa,Daisuke Ishikawa,Takako Sano,Shigeki Nanjo,Tadaaki Yamada,Hiromichi Ebi,Lu Zhao,Kazuo Yasumoto,Kunio Matsumoto,Kazuhiko Yonekura,Seiji Yano　Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer　9　6　775　2014/06
  • 　Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.　Koji Fukuda,Sakiko Otani,Shinji Takeuchi,Sachiko Arai,Shigeki Nanjo,Azusa Tanimoto,Akihiro Nishiyama,Katsuhiko Naoki,Seiji Yano　Cancer science　112　9　3784　2021/06/19
  • 　A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.　Hiroyuki Yasuda,Eiki Ichihara,Jun Sakakibara-Konishi,Yoshitaka Zenke,Shinji Takeuchi,Masahiro Morise,Katsuyuki Hotta,Mineyoshi Sato,Shingo Matsumoto,Azusa Tanimoto,Reiko Matsuzawa,Katuyuki Kiura,Yuta Takashima,Seiji Yano,Junji Koyama,Takahiro Fukushima,Junko Hamamoto,Hideki Terai,Shinnosuke Ikemura,Ryo Takemura,Koichi Goto,Kenzo Soejima　Lung cancer (Amsterdam, Netherlands)　162　140　2021/12
  • 　MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.　Akihiro Nishiyama,Shinji Takeuchi,Yuta Adachi,Sakiko Otani,Azusa Tanimoto,Motoko Sasaki,Shingo Matsumoto,Koichi Goto,Seiji Yano　Cancer science　111　10　3813　2020/07/31
  • 　Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplification.　Makoto Yamamoto,Takeshi Terashima,Tatsuya Yamashita,Akihiro Seki,Hidetoshi Nakagawa,Kouki Nio,Tetsuro Shimakami,Hajime Takatori,Kuniaki Arai,Eishiro Mizukoshi,Masao Honda,Shinji Takeuchi,Taro Yamashita　Hepatology research : the official journal of the Japan Society of Hepatology　54　3　315　2023/10/10
  • 　Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.　Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S　Cancer Research　2019/04/01
  • 　Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.　Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.　Am J Pathol.　181　3　1034-43　2012/07/09
  • 　EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.　Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S.　Cancer Res.　73　8　2428-34　2013/04/15
  • 　mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.　Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S.　PLoS One.　8　5　e62104　2013/05/14
  • 　Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.　Sachiko Arai,Shinji Takeuchi,Koji Fukuda,Hirokazu Taniguchi,Akihiro Nishiyama,Azusa Tanimoto,Miyako Satouchi,Kaname Yamashita,Koshiro Ohtsubo,Shigeki Nanjo,Toru Kumagai,Ryohei Katayama,Makoto Nishio,Mei-Mei Zheng,Yi-Long Wu,Hiroshi Nishihara,Takushi Yamamoto,Mitsutoshi Nakada,Seiji Yano　Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer　15　5　752　2020/05
  • 　Comprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practice.　Takeshi Terashima,Tatsuya Yamashita,Kuniaki Arai,Noboru Takata,Tomoyuki Hayashi,Akihiro Seki,Hidetoshi Nakagawa,Kouki Nio,Noriho Iida,Shinya Yamada,Tetsuro Shimakami,Hajime Takatori,Kunihiro Tsuji,Hajime Sunagozaka,Eishiro Mizukoshi,Masao Honda,Shinji Takeuchi,Taro Yamashita　Hepatology international　19　1　212　2024/11/14
  • 　Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer.　Koji Fukuda,Shinji Takeuchi,Sachiko Arai,Kenji Kita,Azusa Tanimoto,Akihiro Nishiyama,Seiji Yano　Cancer science　111　7　2374　2020/07
  • 　Case report: Navigating treatment pathways for cardiac intimal sarcoma with PDGFRβ N666K mutation.　Akihiro Nishiyama,Shigeki Sato,Hiroyuki Sakaguchi,Hiroshi Kotani,Kaname Yamashita,Koushiro Ohtsubo,Keishi Mizuguchi,Hiroko Ikeda,Kenji Iino,Hirofumi Takemura,Shinji Takeuchi　Frontiers in oncology　14　1362347　2024
  • 　Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.　Azusa Tanimoto,Shingo Matsumoto,Shinji Takeuchi,Sachiko Arai,Koji Fukuda,Akihiro Nishiyama,Kiyotaka Yoh,Takaya Ikeda,Naoki Furuya,Kazumi Nishino,Yuichiro Ohe,Koichi Goto,Seiji Yano　Clinical cancer research : an official journal of the American Association for Cancer Research　27　5　1410　2020/12/11
  • 　Case Report: Medullary carcinoma of the pancreas with MLH1 promoter hypermethylation, induced deficient mismatch repair, successfully treated with an immune checkpoint inhibitor.　Koushiro Ohtsubo,Shigeki Sato,Hiroyuki Sakaguchi,Hiroshi Kotani,Akihiro Nishiyama,Kaname Yamashita,Seiji Yano,Fumihito Toshima,Dai Inoue,Toshifumi Gabata,Hiroko Ikeda,Atsushi Watanabe,Kenji Notohara,Takao Fujisawa,Yoshiaki Nakamura,Takayuki Yoshino,Kunio Miyake,Kazuhiro Miwa,Shinji Takeuchi　Frontiers in oncology　15　1551038　2025

Conference Presentations

Others

Arts and Fieldwork

Patent

Theme to the desired joint research

Grant-in-Aid for Scientific Research

○2022「ALK肺がんのアポトーシス抵抗性因子を標的とした新規治療の開発」(2020-2022)　
○「miR-201sを標的とした肺癌のEMTに起因するTKI耐性克服治療の開発」(2018-2020)　
○「アポトーシス抵抗性に起因する変異型選択的EGFR-TKI耐性克服治療の開発」(2017-2019)　
○「EGFR変異肺癌のアポトーシス抵抗性に起因する次世代型EGFR-TKI耐性の克服」(2017-2019)　
○「EGFR変異肺癌のBIM遺伝子多型に起因するEGFR-TKI耐性克服治療の開発」(2013-2014)
○「Rasシグナル活性化変異を有する原発性肺癌を標的とした新規治療法の開発」(2011-2012)　

Competitive research funding,Contribution

Collaborative research,Consignment study

Classes (Bachelors)

Classes (Graduate Schools)

○Seminar on Clinical Oncology(2017)
○Seminar on Clinical Oncology(2016)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top